The Limited Times

Now you can see non-English news...

Cancer: Big Pharma rush towards "conjugated antibodies"

2021-03-03T19:55:21.820Z

This new class of treatment could weigh 20 billion euros by 2030. Acquisitions are linked. It's a new hope to beat cancer. And a stake in the battle between pharmaceutical companies. "Conjugated antibodies" represent an emerging class of treatment whose first research dates back to the 1990s. They are molecules capable of precisely targeting cancer cells in order to destroy them: they deliver chemotherapy inside these cells. , which helps to preserve healthy cells and reduce the side ef



It's a new hope to beat cancer.

And a stake in the battle between pharmaceutical companies.

"Conjugated antibodies" represent an emerging class of treatment whose first research dates back to the 1990s. They are molecules capable of precisely targeting cancer cells in order to destroy them: they deliver chemotherapy inside these cells. , which helps to preserve healthy cells and reduce the side effects of chemotherapy.

Read also: The new promises of immunotherapy

While they do not cure patients, these treatments have had encouraging results in lymphoma, leukemia and breast cancer.

Some doctors are already seeing them replace chemotherapy in the long term.

"All the laboratories positioned on the oncology market are interested in it,"

explains Éric Le Berrigaud, analyst at Bryan, Garnier & Co.

There are certain turns that should not be missed, as were before certain targeted therapies.

This article is for subscribers only.

You have 71% left to discover.

Subscribe: 1 € the first month

Can be canceled at any time

I ENJOY IT

Already subscribed?

Log in

Source: lefigaro

All business articles on 2021-03-03

You may like

News/Politics 2021-02-17T18:07:31.586Z

Trends 24h

Latest

© Communities 2019 - Privacy